focus -WSS

focus

author：focus 2025-10-01 04:10:44 - browse：191

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Free medical tuition alone isn't enough to close gaps in primary care

WSS

As H5N1 spreads in cows, experts warn against drinking raw milk

STAT Summit: How a Chicago ER doctor tackles gun violence

Supreme Court to hear if Covid misinformation is protected speech

As H5N1 spreads in cows, experts warn against drinking raw milk

The EU Joint Clinical Assessment needs to live up to its promise

WuXi Biologics execs register to lobby as Congress comes for the company

focus

focus

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Studies point to risks of excluding people with obesity from drug trials

Dobbs anniversary: the lost opportunity of abortion as health care

Fertility clinic egg and embryo storage is a disaster

Peter Hotez and the public health issue of online harassment

Hottest summer in 2,000 years puts focus on extreme heat, health

State Dept. review finds Biden bears some blame for Afghanistan failures

Eli Lilly expects to double planned employment in Boston center

Psychedelics group wrestles with new pharma identity

STAT Summit: Michael J. Fox on progress in Parkinson's research

hotspot

Beam Therapeutics to lay off 20% of its staff, re

Beam Therapeutics to lay off 20% of its staff, re

Abbott's new stent may help patients with peripheral artery disease

The EU Joint Clinical Assessment needs to live up to its promise

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

2023 STAT Wunderkinds: get to know the winners

explore

explore

hotspot

hotspot